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Abstract
Aims/hypothesis This study was designed to investigate
the effect of short-term ACE inhibitor treatment on insulin
sensitivity and to examine possible underlying metabolic
and haemodynamic effects in obese insulin-resistant
subjects.
Methods A randomised, double-blind placebo-controlled
trial was performed in 18 obese insulin-resistant men (age,
53±2 years; BMI, 32.6±0.8 kg/m2; homeostasis model
assessment of insulin resistance, 5.6±0.5; systolic blood
pressure [SBP], 140.8±3.2; diastolic blood pressure [DBP],
88.8±1.6 mmHg), who were free of any medication. The
aim was to examine the effects of 2 weeks of ACE inhibitor
treatment (ramipril, 5 mg/day) on insulin sensitivity,
forearm blood flow, substrate fluxes across the forearm,
whole-body substrate oxidation and intramuscular triacyl-
glycerol (IMTG) content.
Results Ramipril treatment decreased ACE activity com-
pared with placebo (−22.0±1.7 vs 0.2±1.1 U/l, respective-
ly, p<0.001), resulting in a significantly reduced blood
pressure (SBP, −10.8±2.1 vs −2.7±2.0 mmHg, respectively,
p=0.01; DBP, −10.1±1.3 vs −4.2±2.1 mmHg, respectively,
p=0.03). Ramipril treatment had no effect on whole-body
insulin-mediated glucose disposal (before: 17.9±2.0, after:
19.1±2.4 μmol kg body weight−1 min−1, p=0.44), insulin-
mediated glucose uptake across the forearm (before: 1.82±
0.39, after: 1.92±0.29 μmol 100 ml forearm tissue−1 min−1,
p=0.81) and IMTG content (before: 45.4±18.8, after:
48.8±27.5 μmol/mg dry muscle, p=0.92). Furthermore,
the increase in carbohydrate oxidation (p<0.001) and
forearm blood flow (p<0.01), and the decrease in fat
oxidation (p<0.001) during insulin stimulation were not
significantly different between treatments.
Conclusions/interpretation Short-term ramipril treatment
adequately reduced ACE activity and blood pressure, but
had no significant effects on insulin sensitivity, forearm
blood flow, substrate fluxes across the forearm, whole-body
substrate oxidation and IMTG content in obese insulin-
resistant subjects.
Keywords ACE inhibition . Insulin sensitivity .
Muscle blood flow . Skeletal muscle glucose uptake .
Substrate oxidation
Abbreviations
DBP diastolic blood pressure
FBF forearm blood flow
HOMA-IR homeostasis model assessment of insulin
resistance
IMTG intramuscular triacylglycerol
RAS renin–angiotensin system
SBP systolic blood pressure
TAG triacylglycerol
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Introduction
Type 2 diabetes mellitus is associated with an increased
cardiovascular risk, which is increased in the presence of
hypertension [1]. On the other hand, hypertension is a
strong predictor of the development of diabetes, indicated
by a 2.5-fold increased risk of developing type 2 diabetes in
hypertensive compared with normotensive individuals [2].
Angiotensin-converting enzyme inhibitors are increas-
ingly used as first-line therapy for hypertension in patients
with type 2 diabetes mellitus, mainly because they have
been shown to reduce both microvascular and macro-
vascular complications in diabetes [1]. On the other hand,
recent clinical trials have suggested that agents interfering
with the renin–angiotensin system (RAS), such as ACE
inhibitors and angiotensin II type 1 receptor blockers, may
reduce the incidence of diabetes in patients with or without
hypertension and at high risk of developing diabetes [3].
The beneficial effects of RAS blockade on the develop-
ment of diabetes have mainly been explained by haemody-
namic and metabolic effects that improve insulin sensitivity
and/or insulin secretion. First, ACE inhibition may increase
skeletal muscle and pancreatic blood flow [4, 5], which in
turn may increase glucose and insulin delivery to the
periphery. Second, RAS blockade may improve peripheral
glucose metabolism (Table 1) [6–13]. Thirdly, it has recently
been hypothesised that RAS blockade may prevent diabetes
by promoting adipocyte differentiation [14], thereby counter-
acting ectopic fat deposition. Finally, RAS blockade may
improve pancreatic islet morphology and function, thereby
increasing insulin secretion [5]. Improvement of whole-body
potassium stores after chronic ACE inhibition may be one of
the underlying mechanisms in this case [15].
However, many studies have shown that ACE inhibition
has no beneficial effects on insulin sensitivity and the
development of diabetes (Table 1) [15–24]. Unfortunately,
several investigations on this issue are based on uncon-
trolled study designs and surrogate markers of insulin
sensitivity, and are potentially confounded by the use of
additional medication.
Because results are still controversial, it is important to
examine the effect of RAS blockade on insulin sensitivity
and possible underlying mechanisms in vivo in humans.
In the present study, therefore, we investigated the effects
of short-term ACE inhibitor treatment on whole-body
insulin sensitivity, forearm blood flow, substrate fluxes
across the forearm, substrate oxidation, and intramuscular
triacylglycerol (IMTG) content in obese insulin-resistant
subjects.
Subjects and methods
Subjects
Eighteen non-smoking obese insulin-resistant male subjects
participated in this study. Subjects were recruited by
advertisement. Subjects’ characteristics are summarised in
Table 2. Predefined entry criteria at screening were a
BMI >30 kg/m2, a mean supine blood pressure (in trip-
Table 1 Summary of randomised clinical trials that have examined the effect of ACE inhibitor treatment on insulin sensitivity
Authors ACE inhibitor Subjects Duration Blinding Comparison Insulin sensitivity
effect
DeMattia et al. 1996 [6] Captopril, 50 mg/day Type 2 diabetic 10 days Double Placebo 41% increase
Paolisso et al. 1995 [7] Lisinopril, 20 mg/day Hypertensive 2 weeks Single Placebo 33% increase
Vuorinen-Markkola et al.
1995 [8]
Enalapril, 20–40 mg/day Hypertensive,
type 2 diabetic
4 weeks Double Placebo 30% increase
Falkner et al. 1995 [9] Lisinopril 10–40 mg/day Hypertensive 12 weeks Single Placebo 16% increase
Ferri et al. 1995 [10] Captopril, 2×25 mg/day Type 2 diabetic 1 week Double Placebo 14% increase
Pollare et al. 1989 [11] Captopril, 2×25–50 mg/day Hypertensive 4 weeks Double Placebo 11% increase
Petrie et al. 2000 [16] Trandolapril, 2 mg/day Hypertensive,
IGT/type 2 diabetic
4 weeks Double Placebo No change
New et al. 2000 [17] Trandolapril, 4 mg/day Hypertensive,
type 2 diabetic
19 days Double Placebo No change
Wiggam et al. 1998 [18] Captopril, 100 mg/day Hypertensive 8 weeks Double Placebo No change
Santoro et al. 1992 [15] Cilazapril, 5 mg/day Hypertensive 12weeks Open Placebo No change
Ludvik et al. 1991 [19] Ramipril, 5 mg/day Hypertensive 2 weeks Open Before
treatment
No change
Valensi et al. 1996 [20] Ramipril, 1.25 mg/day Obese 10 days Double Placebo No change
Pratt et al. 1993 [21] Captopril, 12.5 mg/day Healthy 4 weeks Single Enalapril No change
Heinemann et al. 1995 [22] Lisinopril, 5 mg/day Healthy 4 weeks Double Bisoprolol No change
In this overview, only studies using the hyperinsulinaemic–euglycaemic clamp technique to assess insulin sensitivity were included.
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licate after 10 min of supine rest) >120/80 mmHg, and
insulin resistance calculated by homeostasis model assess-
ment (HOMA-IR) [25] (inclusion when HOMA-IR >2.2).
Eight subjects (four in each treatment group) were mildly
hypertensive (blood pressure >140/90 mmHg). Exclusion
criteria were cardiovascular disease, diabetes mellitus,
cancer, asthma or bronchitis, low-sodium diet, participation
in organised sports activities lasting more than three hours a
week, or the use of any medication. The Medical–Ethical
Committee of Maastricht University approved the study
protocol, and all subjects gave written informed consent
before participating in the study.
Study design
This study had a double-blind, placebo-controlled, ran-
domised design. Following screening, subjects were ran-
domly divided into two groups. One group received the ACE
inhibitor ramipril (5 mg daily, single oral dose; Sanofi-
Aventis, Gouda, the Netherlands) for 14 days, while the
control group received placebo treatment during this period.
Subjects came to the laboratory on two occasions (before
and after treatment). These visits were in the morning after
an overnight fast. Subjects travelled to the laboratory by car
or bus, and were asked: (1) to refrain from drinking alcohol
for a period of 24 h before each study day; (2) to perform
no strenuous exercise for a period of 48 h before each study
day; and (3) not to change their dietary and physical
activity habits throughout the study. On arrival, height,
weight, and waist and hip circumferences were measured.
After 30 min of supine rest blood pressure was measured
with an electronic auscultatory blood pressure reading
machine (Omron Healthcare Europe, Hoofddorp, the
Netherlands). Before and after treatment, insulin sensitivity
was determined by a 3-h hyperinsulinaemic–euglycaemic
clamp, using a modification of the method described by
DeFronzo et al. [26]. For the measurement of IMTG
content at baseline, a muscle biopsy was collected from
the m. vastus lateralis under local anaesthesia using needle
biopsy.
Hyperinsulinaemic–euglycaemic clamp
Three cannulas were inserted before the start of the
experiment. A 20-gauge cannula was inserted retrograde-
ly into a superficial dorsal hand vein, which was heated
in a hot-box (60°C) to obtain arterialised venous blood.
In the same arm, a second cannula was introduced
anterogradely in an antecubital vein of the forearm for
the infusion of 20% glucose (IVAC560 pump; IVAC, San
Diego, CA, USA) and insulin (40 mU m−2 min−1;
Actrapid, Novo Nordisk Farma, Alphen aan den Rijn,
the Netherlands) using a microinfusion pump (Harvard;
Plato, Diemen, the Netherlands). In the contralateral arm,
a third cannula was inserted retrogradely in an ante-
cubital vein of the forearm to obtain deep venous blood,
draining forearm muscle. A small amount of blood was
drawn from the dorsal hand vein every 5 min throughout
the clamp to determine glucose concentration (EML 105;
Radiometer, Copenhagen, Denmark). The amount of
glucose infused was adjusted to maintain euglycaemia
at 5.0 mmol/l.
Before the start of the clamp (t −30, t −20, t −10 min),
and at three time points during the last 30 min of the clamp
(t 150, t 160, t 170 min) when a steady state in glucose
concentration was reached, arterialised and deep venous
blood samples were simultaneously collected to assess
arterio-venous differences of metabolites across the fore-
arm. At the same time points, forearm blood flow (FBF)
was measured to calculate substrate fluxes across the
forearm, as previously described [27]. Energy expenditure,
respiratory quotient, and total fat and carbohydrate oxida-
tion were assessed at baseline and during the last 30 min of
the clamp using indirect calorimetry [28, 29].
Biochemical measurements
Blood samples were collected into syringes containing
EDTA, heparin, or angiotensin II buffer [30], and immedi-
ately transferred into ice-chilled polypropylene tubes.
Blood samples were centrifuged (1,000 g, 4°C, 10 min)
and plasma was immediately frozen in liquid nitrogen and
stored at −80°C until analysis. A small proportion of blood
was used to measure oxygen saturation (%HbO2) to ensure
adequate arterialisation (ABL 510; Radiometer).
Angiotensin II was measured by a radioimmunoassay
(Peninsula Laboratories Europe, St Helens, UK) following
C-18 Sep-Pak (Waters-Millipore, Milford, MA, USA)
Table 2 Subjects’ characteristics before treatment
Placebo (n=9) Ramipril (n=9)
Age (years) 53±3 52±3
Weight (kg) 101.2±4.7 108.0±4.5
Height (m) 1.76±0.03 1.82±0.02
BMI (kg/m2) 32.4±0.9 32.8±1.4
Waist (cm) 117.9±4.5 115.3±3.6
Hip (cm) 112.0±3.8 110.2±2.3
SBP (mmHg) 144±5 138±4
DBP (mmHg) 90±2 88±2
Fasting glucose (mmol/l) 6.0±0.1 5.9±0.1
Fasting insulin (mU/l) 21.8±3.0 20.9±1.9
HOMA-IR 5.8±0.8 5.5±0.6
Values are means ± SEM.
SBP, systolic blood pressure (mmHg); DBP, diastolic blood pressure
(mmHg); HOMA-IR, insulin resistance index by homeostasis model
assessment.
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extraction of the peptide. Plasma ACE activity was deter-
mined by a colorimetric assay (ACE color; Fujirebio, Tokyo,
Japan). Plasma glucose (ABX Pentra Glucose HK CP;
Radiometer), NEFA (NEFA C kit; Wako Chemicals, Neuss,
Germany), glycerol (EnzyPlus glycerol kit; Diffchamp,
Västra Frölunda, Sweden) and triacylglycerol (TAG) (ABX
Triglyceriden 100; Radiometer) concentrations were mea-
sured using standard enzymatic methods. Plasma insulin
concentrations were measured by a specific double-antibody
radioimmunoassay (Linco Research, St Charles, MO, USA).
IMTG content
Muscle biopsies were immediately frozen in liquid
nitrogen and stored at −80°C until analysis. IMTG content
was analysed as previously described [31]. Biopsies were
freeze-dried, dissected free of blood, connective tissue and
visible fat under magnification, and powdered for analysis
of IMTG content. IMTG was extracted from a 2 to 6 mg
sample of powdered muscle using Folch extraction [32].
Briefly, after phospholipids removal using silicic acid, the
extracts were saponified with ethanolic KOH at 60°C for
1 h, and neutralised with MgSO4. IMTG concentration was
then determined by assaying free glycerol fluorometrically
with a standard glycerol kit (Boehringer, Mannheim,
Germany) with concentrations of NADH, enzymes and
buffer adjusted for accurate fluorometric detection.
Statistics
Data are presented as mean ± SEM. The overall effects of
ramipril treatment compared with placebo were analysed
using repeated-measures ANOVA to identify time effects,
treatment effects, and time and treatment interactions.
Changes with time in the measured variables were assessed
by two-way repeated-measures ANOVA, using time as
within-subject factor and treatment as between-subject
factor. Because no significant differences in any of the
measured variables were observed between groups at
baseline, both groups were combined to assess the effect
of insulin (hyperinsulinaemic–euglycaemic clamp) before
the start of the treatment period using Student’s paired
t tests. Calculations were done using SPSS 10.1 for Windows
(SPSS, Chicago, IL, USA). p<0.05 was considered to be
statistically significant.
Results
Subject characteristics
Age, weight, height, BMI, waist and hip circumferences,
blood pressure, plasma glucose and insulin concentrations,
and HOMA-IR were comparable between the ramipril and
placebo group before the start of treatment (Table 2),
indicating that both treatment groups were well-matched
after randomisation. No changes in weight, BMI, or waist
circumference were observed at the end of either treatment.
Plasma ACE and angiotensin II concentrations
Plasma ACE activity was decreased after ramipril treatment
(before: 28.9±1.9, after: 6.9±0.3 U/l, p<0.001), while no
changes in ACE activity were observed after placebo
treatment (Fig. 1). Insulin caused a slight but significant
decrease in ACE activity (baseline: 27.6±1.5 vs insulin:
22.1±1.4 U/l, p<0.001). Plasma angiotensin II concen-
trations were comparable between the ramipril and placebo
group before treatment (10.6±2.6 vs 8.6±2.3 pmol/l respec-
tively, p=0.57). No significant differences in plasma
angiotensin II concentrations were observed after ramipril
treatment compared with placebo (p=0.22).
Blood pressure
Ramipril treatment significantly reduced systolic blood
pressure (SBP) (p=0.01), diastolic blood pressure (DBP)
(p=0.03), and mean arterial blood pressure (p=0.01)
compared with placebo. SBP was reduced by 10.8 mmHg
(137.7±3.9 vs 126.9±3.2 mmHg, p<0.001), and DBP by
10.2 mmHg (87.6±2.3 vs 77.4±2.1 mmHg, p<0.001) after
ramipril treatment. Placebo treatment did not alter blood
pressure.
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Fig. 1 Plasma ACE activity before and after treatment. Ramipril
treatment (filled bars, before; closely hatched bars, after) significantly
decreased ACE activity compared with placebo (grey bars, before;
normally hatched bars, after) (p<0.001 by two-way repeated
measures ANOVA). Values are means ± SEM. *p<0.05 vs baseline,
***p<0.001 vs before treatment, both Student’s paired t test
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Whole-body insulin sensitivity
As expected from screening results, whole-body insulin
sensitivity measurements showed that all subjects were
insulin-resistant. There were no significant differences in
whole-body insulin-mediated glucose disposal after ram-
ipril treatment compared with placebo (p=0.90) (Fig. 2).
Arterialised plasma insulin, glucose, TAG, NEFA
and glycerol concentrations
Plasma insulin concentrations increased to a plateau with-
in the first 60 min of the clamp with no significant dif-
ferences between treatments and study days at baseline
and during hyperinsulinaemia (baseline: 21.3±1.7, hyper-
insulinaemia: 119.9±3.8 mU/l, p<0.001). Hyperinsulinae-
mia decreased plasma concentrations of glucose (baseline:
5.9±0.1, hyperinsulinaemia: 5.4±0.1 mmol/l, p=0.001),
TAG (baseline: 1315±85, hyperinsulinaemia: 1196±
80 μmol/l, p=0.02), NEFA (baseline: 558±30, hyper-
insulinaemia: 166±16 μmol/l, p<0.001) and glycerol (base-
line: 91.6±2.7, hyperinsulinaemia: 60.7±3.4 μmol/l,
p<0.001). No significant differences in plasma metabolite
concentrations were observed between ramipril and placebo
treatment at baseline and during hyperinsulinaemia.
Forearm blood flow
FBF was increased during insulin stimulation (baseline:
2.1±0.2, hyperinsulinaemia: 2.5±0.1 ml 100 ml forearm
tissue−1 min−1, p<0.01). Baseline FBF (p=0.14) and the
increase in FBF during insulin-stimulation (p=0.38) were
not significantly different after ramipril treatment compared
with placebo (Fig. 3).
Substrate fluxes across the forearm
Insulin-stimulation increased forearm glucose uptake (base-
line: 0.28±0.06, hyperinsulinaemia: 1.99±0.33 μmol 100 ml
forearm tissue−1 min−1, p<0.001) (Fig. 4) and lactate release
(baseline: −0.03±0.04 vs hyperinsulinaemia: −0.12±
0.03 μmol 100 ml forearm tissue−1 min−1, p=0.04), but
had no significant effects on TAG, NEFA and glycerol
fluxes across the forearm (data not shown). Ramipril
treatment did not significantly affect basal and insulin-
stimulated glucose uptake (Fig. 4) and other substrate fluxes
(data not shown) across the forearm compared with
placebo.
Energy expenditure and whole-body substrate oxidation
Energy expenditure was not different from baseline during the
clamp (baseline: 5.7±0.1, hyperinsulinaemia: 5.7±0.1 kJ/min,
p=0.53). As expected, insulin-stimulation increased the respi-
ratory quotient (baseline: 0.81±0.01, hyperinsulinaemia: 0.87±
0.01, p<0.001) and carbohydrate oxidation (baseline: 0.12±
0.01, hyperinsulinaemia: 0.19±0.01 g/min, p<0.001), and
decreased fat oxidation (baseline: 0.07±0.00, hyperinsulinaemia:
0.04±0.00 g/min, p<0.001). Ramipril treatment had no
significant effect on energy expenditure, or carbohydrate and
fat oxidation, compared with placebo.
IMTG content
IMTG content was not significantly different between the
ramipril and placebo group before treatment (45.4±18.8 vs
34.7±7.5 μmol/mg dry muscle respectively, p=0.60). No
0
5
10
15
20
25
30
Ramipril Placebo
Fig. 2 Whole-body glucose infusion rate as a marker of insulin-
stimulated glucose disposal before (dark bars) and after (grey bars)
treatment. Ramipril treatment had no significant effect on insulin-
stimulated glucose disposal compared with placebo (p=0.90 by two-
way repeated measures ANOVA). Values are means ± SEM
0.0
0.5
1.0
1.5
2.0
2.5
3.0
3.5
Baseline Clamp
Fig. 3 Forearm blood flow before and after treatment. Baseline
forearm blood flow (FBF) (p=0.14 by two-way repeated measures
ANOVA) and the increase in FBF after insulin-stimulation (p=0.38 by
two-way repeated measures ANOVA) were not significantly different
after ramipril treatment (closely hatched bars; before ramipril, filled
bars) compared with placebo (before, grey bars; after, normally
hatched bars). Values are means ± SEM
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significant differences in IMTG content were observed after
ramipril treatment compared with placebo (48.8±27.5 vs
37.1±12.2 μmol/mg dry muscle respectively, p=0.98).
Discussion
The present study showed that in obese insulin-resistant
subjects short-term treatment with the ACE inhibitor
ramipril adequately decreases ACE activity and blood
pressure, but has no significant effects on insulin sensitivity,
plasma metabolite concentrations, FBF, glucose uptake
across the forearm, whole-body substrate oxidation, and
IMTG content.
Long-term clinical trials have demonstrated beneficial
effects of RAS blockade on the development of type 2
diabetes [3]. Previous studies that examined the effect of
ACE inhibitors on insulin sensitivity have yielded
conflicting results (Table 1). In the present study no
significant effect of short-term ACE inhibition on insulin
sensitivity was found, a finding which is consistent with
evidence from other well-designed trials in obese subjects
[20], non-diabetic hypertensive patients [18] and in type 2
diabetic patients with hypertension [16, 17]. Despite
controversial findings, several mechanisms have been
proposed that may be responsible for the potential
beneficial metabolic effects of ACE inhibitors.
First, there is evidence to suggest that RAS blockade
may increase muscle blood flow [4], which in turn may
increase glucose uptake in this tissue [33], as peripheral
vascular changes may affect insulin sensitivity [34]. In line
with previous reports, the present data show that neither
baseline nor insulin-stimulated FBF were increased after
ACE inhibition [15, 35, 36]. An explanation for the lack of
FBF increase after ramipril treatment in the present study
could be that the marked decrease in blood pressure caused
by a reduced total peripheral resistance prevents an increase
in FBF.
Second, RAS blockade may directly stimulate glucose
uptake. Several animal and cell studies have demonstrated
that angiotensin II may induce insulin resistance by direct
impairment of insulin signalling. This notion is supported
by findings of increased GLUT4 protein expression and
improved skeletal muscle glucose disposal after RAS
blockade (reviewed in [37]). We found that ACE inhibitor
treatment had no clinically relevant effects on whole-body
insulin sensitivity in obese insulin-resistant subjects. Fur-
thermore, the lack of improvement in baseline and insulin-
stimulated glucose uptake across the forearm suggests that
ramipril treatment does not improve insulin signalling in
skeletal muscle. This is consistent with reports demonstrat-
ing that ACE inhibition had no effect on insulin sensitivity
in non-obese non-diabetic hypertensive patients [19] and on
muscle glucose uptake in diabetic patients [35].
Third, alterations in adipose tissue biology may underlie
changes in insulin sensitivity. It has been shown that
angiotensin II inhibits differentiation of human preadipo-
cytes [38]. This may lead to increased storage of TAG in
other tissues such as skeletal muscle, thereby causing
insulin resistance [14]. Therefore, similarly to the working
mechanism of the thiazolidinedione insulin-sensitisers [39],
blockade of the RAS may reverse insulin resistance by
counteracting ectopic fat deposition. We found no signifi-
cant effect of ACE inhibition on IMTG content. Although
no data are available on the time-course of changes in
IMTG content evoked by drug treatment under a relatively
stable lifestyle situation, we cannot exclude the possibility
that the duration of ACE inhibitor treatment may have been
too short to observe a change in IMTG content. It is
important to recognise that although the within-biopsy
variability of the IMTG measurements was small in the
present study (<5%), IMTG measurements as such can be
highly variable [40, 41], especially when conducted by
untrained individuals, thus possibly hampering detection of
small changes in IMTG content.
The main limitation of this study is the relatively small
number of subjects studied. The intra-individual variation of
the hyperinsulinaemic–euglycaemic clamp in the present
group of subjects (before and after placebo treatment) was
12.2±3.7%, indicating that small changes in insulin sensi-
tivity could not be detected in the obese insulin-resistant
subjects studied. Although the present study may have been
0.0
0.5
1.0
1.5
2.0
2.5
3.0
3.5
Baseline Clamp
*
*****
*
Fig. 4 Baseline and insulin-stimulated glucose uptake across the
forearm before and after treatment. Insulin stimulation increased
glucose uptake across the forearm (p<0.001). Baseline glucose uptake
across the forearm (p=0.99 by two-way repeated measures ANOVA)
and the increase in glucose uptake across the forearm after insulin-
stimulation (p=0.79 by two-way repeated measures ANOVA) were
not significantly different after ramipril treatment (closely hatched
bars; before ramipril, filled bars) compared with placebo (before, grey
bars; after, normally hatched bars). Values are means ± SEM.
*p<0.05 vs baseline, **p<0.01 vs baseline, ***p<0.001 vs baseline,
all Student’s paired t test
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slightly underpowered to detect small differences in Tinsulin
sensitivity, the fact that the effects of ACE inhibitor
treatment on whole-body insulin sensitivity (p=0.90),
basal (p=0.99) and insulin-stimulated skeletal muscle
glucose uptake (p=0.79) were far from significant further
strengthens our conclusions of no treatment effect. This
study, moreover, did not attempt to assess the effects of
ACE inhibition on the liver. It would be interesting to
clarify the effect of RAS blockade on hepatic glucose
output in future studies.
In conclusion, short-term ramipril treatment has no
significant effects on insulin sensitivity, FBF, skeletal
muscle glucose uptake, whole-body substrate oxidation,
and IMTG content in obese insulin-resistant subjects. These
findings suggest that the reduced incidence of diabetes after
long-term RAS blockade may be caused by long-term
effects that increase insulin sensitivity and/or secretion.
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